Total Payments
$12,959
2024 Payments
$2,645
Companies
39
Transactions
523
Medicare Patients
4,730
Medicare Billing
$1.4M
Payment Breakdown by Category
Food & Beverage$8,226 (63.5%)
Research$4,323 (33.4%)
Education$392.22 (3.0%)
Gifts$18.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,226 | 503 | 63.5% |
| Unspecified | $4,323 | 11 | 33.4% |
| Education | $392.22 | 8 | 3.0% |
| Gift | $18.00 | 1 | 0.1% |
Payments by Type
General
$8,636
512 transactions
Research
$4,323
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $2,393 | 2 | $0 (2020) |
| Gilead Sciences, Inc. | $1,930 | 9 | $0 (2020) |
| Amgen Inc. | $1,617 | 101 | $0 (2024) |
| Janssen Biotech, Inc. | $1,064 | 55 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $653.46 | 36 | $0 (2024) |
| UCB, Inc. | $600.16 | 48 | $0 (2024) |
| PFIZER INC. | $554.89 | 43 | $0 (2024) |
| ABBVIE INC. | $527.07 | 29 | $0 (2024) |
| Horizon Therapeutics plc | $516.77 | 31 | $0 (2023) |
| Lilly USA, LLC | $430.57 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,645 | 145 | Amgen Inc. ($444.72) |
| 2023 | $2,885 | 154 | Amgen Inc. ($577.25) |
| 2022 | $1,219 | 65 | Amgen Inc. ($289.13) |
| 2021 | $52.98 | 3 | E.R. Squibb & Sons, L.L.C. ($23.85) |
| 2020 | $3,675 | 16 | Gilead Sciences, Inc. ($1,930) |
| 2019 | $836.01 | 5 | Eli Lilly and Company ($762.84) |
| 2018 | $473.32 | 29 | Janssen Biotech, Inc. ($120.75) |
| 2017 | $1,172 | 106 | Amgen Inc. ($185.72) |
All Payment Transactions
523 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $25.41 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $7.42 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/16/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/12/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $8.98 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/12/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $4.49 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $11.95 | General |
| Category: Immunology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $6.95 | General |
| Category: Immunology | ||||||
| 12/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $31.25 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $32.74 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/21/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: Inflammation | ||||||
| 11/20/2024 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Food and Beverage | In-kind items and services | $33.25 | General |
| Category: Biosimilars | ||||||
| 11/20/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $6.71 | General |
| Category: Bone Health | ||||||
| 11/14/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $26.26 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/09/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: Immunology | ||||||
| 11/04/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $22.39 | General |
| Category: Dermatology | ||||||
| 10/31/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $21.87 | General |
| Category: Immunology | ||||||
| 10/31/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $5.48 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $3.66 | General |
| Category: Dermatology | ||||||
| 10/31/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $2.29 | General |
| Category: Immunology | ||||||
| 10/31/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $1.70 | General |
| Category: Immunology | ||||||
| 10/28/2024 | SOBI, INC | KINERET (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: IMMUNOLOGY | ||||||
| 10/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: IMMUNOLOGY | ||||||
| 10/21/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $6.31 | General |
| Category: Bone Health | ||||||
| 10/18/2024 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $2.62 | General |
| Category: Immunology | ||||||
| 10/17/2024 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $43.16 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $2,393 | 2 |
| A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. | Gilead Sciences, Inc. | $1,930 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,033 | 4,926 | $284,852 | $131,404 |
| 2022 | 23 | 1,123 | 11,124 | $1.2M | $357,613 |
| 2021 | 28 | 1,292 | 15,336 | $1.7M | $486,950 |
| 2020 | 27 | 1,282 | 13,045 | $1.4M | $406,674 |
Total Patients
4,730
Total Services
44,431
Medicare Billing
$1.4M
Procedure Codes
98
All Medicare Procedures & Services
98 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 269 | 505 | $75,709 | $47,220 | 62.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 22 | 1,741 | $43,525 | $31,375 | 72.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 65 | 65 | $14,625 | $8,084 | 55.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 91 | 112 | $12,284 | $7,083 | 57.7% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 47 | 131 | $13,100 | $6,580 | 50.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 13 | 60 | $36,000 | $6,247 | 17.4% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 18 | 51 | $11,750 | $4,628 | 39.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 25 | $5,000 | $3,353 | 67.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 12 | 57 | $11,970 | $2,841 | 23.7% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 44 | 73 | $8,614 | $2,757 | 32.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 139 | 208 | $8,320 | $2,229 | 26.8% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 54 | 54 | $10,800 | $2,017 | 18.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 64 | $8,320 | $1,443 | 17.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 141 | 1,678 | $15,910 | $1,337 | 8.4% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 16 | 16 | $1,600 | $1,213 | 75.8% |
| 73130 | X-ray of hand, minimum of 3 views | Office | 2023 | 13 | 26 | $2,080 | $770.90 | 37.1% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 11 | 13 | $2,025 | $718.07 | 35.5% |
| 73562 | X-ray of knee, 3 views | Office | 2023 | 11 | 18 | $1,440 | $586.08 | 40.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 16 | 16 | $480.00 | $470.40 | 98.0% |
| 72110 | X-ray of lower and sacral spine, minimum of 4 views | Office | 2023 | 13 | 13 | $1,300 | $451.00 | 34.7% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 11 | 6,825 | $887,250 | $236,112 | 26.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 275 | 506 | $75,859 | $48,140 | 63.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 12 | 1,081 | $27,025 | $18,607 | 68.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 151 | 201 | $22,074 | $13,072 | 59.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 67 | 67 | $15,075 | $8,156 | 54.1% |
About Dr. Violette Henein, M.D
Dr. Violette Henein, M.D is a Rheumatology healthcare provider based in Clinton Township, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1912914227.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Violette Henein, M.D has received a total of $12,959 in payments from pharmaceutical and medical device companies, with $2,645 received in 2024. These payments were reported across 523 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($8,226).
As a Medicare-enrolled provider, Henein has provided services to 4,730 Medicare beneficiaries, totaling 44,431 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 98 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Clinton Township, MI
- Active Since 08/01/2006
- Last Updated 01/05/2010
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1912914227
Products in Payments
- TREMFYA (Drug) $627.76
- KRYSTEXXA (Biological) $614.64
- Enbrel (Biological) $592.90
- Cimzia (Drug) $558.59
- XELJANZ (Drug) $529.57
- EVENITY (Biological) $402.87
- TALTZ (Drug) $378.07
- RINVOQ (Biological) $373.14
- COSENTYX (Drug) $358.98
- BENLYSTA (Biological) $318.61
- SAPHNELO (Biological) $312.48
- ORENCIA (Biological) $281.29
- STELARA (Biological) $233.45
- COSENTYX (Biological) $227.12
- IDACIO (Biological) $186.74
- TAVNEOS (Drug) $181.09
- Otezla (Drug) $154.41
- Actemra (Biological) $152.39
- REMICADE (Biological) $114.67
- Rituxan (Biological) $100.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.